Tango Therapeutics TNGX Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's other income (expense)?
- Tango Therapeutics (TNGX) reported other income (expense) of $3.26M in Q1 2026.
- How has Tango Therapeutics's other income (expense) changed year-over-year?
- Tango Therapeutics's other income (expense) increased by 21.1% year-over-year, from $2.69M to $3.26M.
- What is the long-term trend for Tango Therapeutics's other income (expense)?
- Over 4 years (2021 to 2025), Tango Therapeutics's other income (expense) has grown at a 150.3% compound annual growth rate (CAGR), from $247K to $9.7M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.